Year: 2025

Scandinavian Tobacco Group announces financial ambitions and new flexible shareholder return policy ahead of Capital Markets Day

Written by Customer Service on November 19, 2025. Posted in Public Companies.

Company Announcement No. 17/2025 Copenhagen, 19 November 2025 Scandinavian Tobacco Group announces financial ambitions and new flexible shareholder return policy ahead of Capital Markets Day Scandinavian Tobacco Group will launch its next five-year strategy, Focus2030, at the upcoming Capital Markets Day on 20 November 2025. The strategy aims to create a company that in 2030 has:A sustainable and stable machine-rolled and smoking tobacco business primarily focused on Europe A growing and increasingly attractive handmade cigar business anchored in the US, with a stronger global footprint A bigger nicotine pouch business with even more upside in an attractive categoryTo support the execution of the Focus2030 strategy, the Board of Directors has today adopted the Group’s financial ambitions and a new shareholder return policy for...

Municipality Finance issues EUR 30 million notes under its MTN programme

Written by Customer Service on November 19, 2025. Posted in Public Companies.

Municipality Finance PlcStock exchange release 19 November 2025 at 10:00 am (EET) Municipality Finance issues EUR 30 million notes under its MTN programme Municipality Finance Plc issues EUR 30 million notes on 20 November 2025. The maturity date of the notes is 20 November 2035. MuniFin has a right, but no obligation, to redeem the notes early on 20 May 2029. The notes bear interest at a fixed rate of 3.09% per annum. The notes are issued under MuniFin’s EUR 50 billion programme for the issuance of debt instruments. The offering circular, the supplemental offering circular and the final terms of the notes are available in English on the company’s website at https://www.kuntarahoitus.fi/en/for-investors. MuniFin has applied for the notes to be admitted to trading on the Helsinki Stock Exchange maintained by Nasdaq Helsinki. The...

Heineken® 0.0 partners with Playtomic to bring exclusive benefits to padel players across the globe

Written by Customer Service on November 19, 2025. Posted in Public Companies.

Heineken® 0.0 partners with PlaytomicHeineken® 0.0 partners with Playtomic to bring exclusive benefits to padel players across the globeHeineken® 0.0 has entered a multi-year deal with Playtomic, expanding its sponsorships in padel across every level of the sport Padel players will benefit from exclusive social moments designed by Heineken® 0.0 and Playtomic to elevate padel experiences around the world The partnership kicks off in December featuring the launch of Open Matches by Heineken® 0.0 in BarcelonaAMSTERDAM, Nov. 19, 2025 (GLOBE NEWSWIRE) — Heineken® 0.0 has expanded its global presence in padel, announcing a partnership with Playtomic, the world’s largest global racket-sports community set to launch with an interactive event in December. Playtomic is the leading racket sports booking platform and provides Heineken®...

P95 and Julius Clinical Merge to Form Global, Science-Led CRO Delivering Integrated Clinical Development and Real-World Evidence

Written by Customer Service on November 19, 2025. Posted in Mergers And Acquisitions.

500+ person global organization spans 25+ countries with operations across North America, Europe, Africa, Latin America, and Asia-PacificP95 and Julius ClinicalMerger to Form Global, Science-Led CRO Delivering Integrated Clinical Development and Real-World EvidenceLeuven, Belgium and Zeist, The Netherlands, Nov. 19, 2025 (GLOBE NEWSWIRE) — P95 and Julius Clinical today announced that they have merged to form a leading global, full-service clinical research organization (CRO) with integrated expertise across neuroscience, cardio-renal-metabolic, and infectious diseases and vaccines. The combined organization includes more than 500 professionals in over 25 countries and delivers clinical development and real-world evidence (RWE) programs across five continents. This merger brings together the complementary strengths of...

Nearly 70% of marketing leaders agree agentic AI will be transformative, yet effectiveness remains elusive

Written by Customer Service on November 19, 2025. Posted in Public Companies.

Press contact:Antara NandyTel.:+ 91 9674515119 E-mail: antara.nandy@capgemini.com Nearly 70% of marketing leaders agree agentic AI will be transformative, yet effectiveness remains elusiveCMOs are constrained by ineffectiveness, with only 15% of marketing leaders strongly agreeing that their set up today allows them to do high value work 7 in 10 organizations now use generative AI (Gen AI) in marketing, yet just 7% of marketers strongly agree that AI has boosted marketing effectiveness Only 18% of marketing leaders strongly believe they are successfully personalizing customer interactions using AI/GenAI to boost engagement and outcomes With less than 40% of CMOs controlling martech budgets, CIO-CMO collaboration is critical for AI-driven marketing outcomesParis, November 19, 2025 – The Capgemini Research Institute’s CMO Playbook,...

Strong results, plan fulfilment. Q3 2025: EBITDA growth of over 17% YoY.

Written by Customer Service on November 19, 2025. Posted in Earnings Releases And Operating Results.

Key events for GEVORKYAN in Q3 2025:Revenue increased by 8.7% YoY to over EUR 63.5 million EBITDA amounted to nearly EUR 23 million, representing YoY growth of over 17% EBITDA margin increased by 2.6 p.p. to 36% Outlook for fiscal year 2025: Estimated revenue growth of 11–18%, EBITDA growth of 15–23% 5-year outlook: Estimated annual revenue growth of 10–16%, annual EBITDA growth of 10–18%GEVORKYAN, a.s., a European leader in powder metallurgy, announces selected financial and operating results for the nine months ended 30 September 2025, an updated outlook for fiscal year 2025 and a five-year outlook. The company reported revenue exceeding EUR 63 million for the first nine months of 2025, representing a YoY increase of 8.7%. EBITDA amounted to nearly EUR 23 million, representing a YoY increase of more than 17%, with EBITDA margin...

Wereldhave acquires shopping center Ville2 in Charleroi, Belgium

Written by Customer Service on November 19, 2025. Posted in Mergers And Acquisitions.

Wereldhave N.V. (‘Wereldhave’), through Wereldhave Belgium (69% owned by Wereldhave), has reached agreement with Everbel SA, a Luxembourg family office, on the acquisition of shopping center Ville2 in Charleroi, Belgium. This acquisition is part of the LifeCentral strategy growth phase and is fully compliant with Wereldhave’s rigorous acquisition criteria, including IRR threshold, location, value creation opportunities and Full Service Center transformation potential. This acquisition further strengthens Wereldhave’s leading position in the Walloon region, where the company has been active for nearly 50 years. The total purchase price amounts to € 120m, reflecting a net initial yield of 8.0%. The transaction is expected to close in December 2025. The acquisition of Ville2, together with the disposal of De Roselaar (Roosendaal) and the...

BioPorto Interim Result for the Third Quarter of 2025 – Continued progress and continued NGAL sales growth

Written by Customer Service on November 19, 2025. Posted in Earnings Releases And Operating Results.

November 19, 2025 Announcement no. 26 BioPorto Interim Result for the Third Quarter of 2025 – Continued progress and continued NGAL sales growth. Copenhagen, Denmark, November 19, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), today announced interim financial results for the third quarter of 2025, unchanged from the pre-announced Key Financial Results that were announced on November 4, 2025. Highlights of key strategic milestones and a renewed strategy, “Forward”Delivery of the first ProNephro AKI™ (NGAL) order to the US market in August 2025, marking the first step in the commercial launch. At the end of October 2025, BioPorto successfully completed patient enrollment in its clinical cut-off study. As announced previously, the Company has decided to submit a pre-submission meeting request...

Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical

Written by Customer Service on November 19, 2025. Posted in Mergers And Acquisitions.

Aptose Biosciences minority shareholders to receive C$2.41 in cash per share in a “go private” transaction SAN DIEGO and TORONTO, Nov. 19, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF) and Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) today announced that Aptose, Hanmi and HS North America Ltd., a wholly owned subsidiary of Hanmi (“Hanmi Purchaser” and together with Hanmi, the “Hanmi Purchasers”), have entered into a definitive arrangement agreement (the “Arrangement Agreement”) pursuant to which Hanmi Purchaser will acquire all of the issued and outstanding common shares of Aptose (“Common Shares”) that are not currently owned or controlled by the Hanmi Purchasers or their respective affiliates. Hanmi has participated in multiple financings of Aptose and owns 19.93% of all outstanding...

Vow Q3-25: On a path to restore profitability

Written by Customer Service on November 19, 2025. Posted in Earnings Releases And Operating Results.

Oslo, 19 November 2025 – For Vow ASA (“Vow” or the “Group”), the third quarter 2025 was characterised by high activity across the Group with all-time high revenue in the Maritime Solutions segment. During the quarter, a profit improvement program was launched, and a process of revisiting the strategy has been started, with a particular emphasis on the Industrial Solutions segment. In the third quarter, Vow had revenues of NOK 214.3 million, representing a decline of NOK 53.1 million from Q3 2024. While the Maritime Solutions and Aftersales segments continued their growth trajectory, the progress was offset by negative revenue in the Industrial Solutions segment, as explained in a stock market announcement on 20 October 2025. EBITDA adjusted for non-recurring costs of NOK 2.8 million related to management changes was negative NOK 28.5 million,...

Year: 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals